References

Cancer cachexia: mediators, signaling, and metabolic pathways

10.1016/j.cmet.2012.06.011 · 2012 · External reference

Cancer cachexia: multilevel metabolic dysfunction

10.1038/s42255-024-01167-9 · 2024 · External reference

Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice

10.1002/jcsm.12346 · 2018 · External reference

Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia

10.1084/jem.20190450 · 2021 · External reference

The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy

10.1002/jcsm.12461 · 2019 · External reference

MAP3K11/GDF15 axis is a critical driver of cancer cachexia

10.1002/jcsm.12077 · 2016 · External reference

A waste product’s unexpected role in wasting

10.1038/s42255-024-01010-1 · 2024 · External reference

Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer

10.1038/s41467-022-32135-0 · 2022 · External reference

Excess TGF-β mediates muscle weakness associated with bone metastases in mice

10.1038/nm.3961 · 2015 · External reference

GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates

10.1038/nm.4392 · 2017 · External reference

The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL

10.1038/nm.4393 · 2017 · External reference

A neuroimmune circuit mediates cancer cachexia-associated apathy

10.1126/science.adm8857 · 2025 · External reference

Anti-cytokines in the treatment of cancer cachexia

10.21037/apm.2018.07.06 · 2019 · External reference

Ponsegromab for the treatment of cancer cachexia

10.1056/nejmoa2409515 · 2024 · External reference

Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design

10.1002/jcsm.13435 · 2024 · External reference

A phase Ib first-in-patient study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponsegromab in participants with cancer and cachexia

10.1158/1078-0432.ccr-23-1631 · 2024 · External reference

Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

10.1007/s00520-023-07771-x · 2023 · External reference

The potential prognostic values of the ADAMTS-like protein family: an integrative pan-cancer analysis

10.21037/atm-21-4946 · 2021 · External reference

Cancer-associated cachexia

10.1038/nrdp.2017.105 · 2018 · External reference

Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation

10.1038/s41467-023-38171-8 · 2023 · External reference

The proteomic landscape of monocytes in response to colorectal cancer cells

10.1021/acs.jproteome.4c00400 · 2024 · External reference

Diagnostic criteria for the classification of cancer-associated weight loss

10.1200/jco.2014.56.1894 · 2015 · External reference

An AMP-activated protein kinase–stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice

10.1038/nm.4171 · 2016 · External reference

Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia

10.1016/j.bbadis.2011.08.010 · 2011 · External reference

Definition and classification of cancer cachexia: an international consensus

10.1016/s1470-2045(10)70218-7 · 2011 · External reference

Lipocalin-2 and neutrophil activation in pancreatic cancer cachexia

10.3389/fimmu.2023.1159411 · 2023 · External reference

Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia

10.1002/jcsm.13358 · 2023 · External reference

Transforming growth factor-β signaling in immunity and cancer

10.1016/j.immuni.2019.03.024 · 2019 · External reference

Body composition and lung cancer-associated cachexia in TRACERx

10.1038/s41591-023-02232-8 · 2023 · External reference

Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy

10.1113/jphysiol.2006.116715 · 2006 · External reference

Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90

10.1038/s41467-017-00726-x · 2017 · External reference

Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase

10.1126/science.1123965 · 2006 · External reference

ADAMTSL-6 is a novel extracellular matrix protein that binds to fibrillin-1 and promotes fibrillin-1 fibril formation

10.1074/jbc.m109.076919 · 2010 · External reference

ADAMTSL6β promotes fibrillin-1 microfibril assembly, which is possibly mediated via binding through the third thrombospondin type I domain to fibrillin-1

10.1002/cbin.11337 · 2020 · External reference

Prevalence and prognostic impact of cachexia among older patients with cancer: a nationwide cross-sectional survey (NutriAgeCancer)

10.1002/jcsm.12776 · 2021 · External reference

Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival

10.1016/j.cell.2010.07.011 · 2010 · External reference

The pathophysiology of cancer-mediated cardiac cachexia and novel treatment strategies: a narrative review

10.1002/cam4.6388 · 2023 · External reference

Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation

10.1378/chest.115.3.836 · 1999 · External reference

Direct identification of ligand-receptor interactions on living cells and tissues

10.1038/nbt.2354 · 2012 · External reference

Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex

10.1074/jbc.m110.110288 · 2010 · External reference

A milieu molecule for TGF-β required for microglia function in the nervous system

10.1016/j.cell.2018.05.027 · 2018 · External reference

Thrombospondin-1 regulation of latent TGF-β activation: a therapeutic target for fibrotic disease

10.1016/j.matbio.2017.12.009 · 2018 · External reference

Mechanisms of muscle atrophy and hypertrophy: implications in health and disease

10.1038/s41467-020-20123-1 · 2021 · External reference

Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery

10.1074/mcp.m114.046862 · 2015 · External reference

Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study

10.1371/journal.pone.0035462 · 2012 · External reference

Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy

10.1038/s41434-022-00338-1 · 2022 · External reference

Muscle wasting in disease: molecular mechanisms and promising therapies

10.1038/nrd4467 · 2015 · External reference

Smad2 and 3 transcription factors control muscle mass in adulthood

10.1152/ajpcell.00104.2009 · 2009 · External reference

SMAD3 augments FoxO3-induced MuRF-1 promoter activity in a DNA-binding-dependent manner

10.1152/ajpcell.00391.2013 · 2014 · External reference

Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia

10.1186/1471-2407-14-997 · 2014 · External reference

Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia

10.1074/jbc.m115.641514 · 2015 · External reference

Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo

10.1210/me.2013-1194 · 2013 · External reference

Smad proteins differentially regulate obesity-induced glucose and lipid abnormalities and inflammation via class-specific control of AMPK-related kinase MPK38/MELK activity

10.1038/s41419-018-0489-x · 2018 · External reference

Smad3 deficiency in mice protects against insulin resistance and obesity induced by a high-fat diet

10.2337/db10-0801 · 2011 · External reference

Transforming growth factor-β in tissue fibrosis

10.1084/jem.20190103 · 2020 · External reference

Development of skeletal muscle fibrosis in a rodent model of cancer cachexia

10.1002/cbf.3797 · 2023 · External reference

Skeletal muscle fibrosis in pancreatic cancer patients with respect to survival

10.1093/jncics/pky043 · 2018 · External reference

Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice

1991 · External reference

Adipose tissue fibrosis in human cancer cachexia: the role of TGFβ pathway

10.1186/s12885-017-3178-8 · 2017 · External reference

Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis

10.1002/mus.22232 · 2012 · External reference

Targeting TGFβ signal transduction for cancer therapy

10.1038/s41392-020-00436-9 · 2021 · External reference

On-target anti-TGF-β therapies are not succeeding in clinical cancer treatments: what are remaining challenges?

10.3389/fcell.2020.00605 · 2020 · External reference

Modeling the energetic cost of cancer as a result of altered energy metabolism: implications for cachexia

10.1186/s12976-015-0015-0 · 2015 · External reference

The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth

10.1016/j.ccell.2023.02.016 · 2023 · External reference

Molecular mechanisms of epithelial-mesenchymal transition

10.1038/nrm3758 · 2014 · External reference

Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment

10.1002/1878-0261.13146 · 2022 · External reference

Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer

10.1038/s41598-017-05907-8 · 2017 · External reference

Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease

10.1073/pnas.1620013114 · 2017 · External reference

A novel tissue inhibitor of metalloproteinases-1/liver/cachexia score predicts prognosis of gastrointestinal cancer patients

10.1002/jcsm.12680 · 2021 · External reference